nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—hematopoietic system—hematologic cancer	0.0142	0.0929	CbGeAlD
Lithium—IMPA1—gonad—hematologic cancer	0.0108	0.0706	CbGeAlD
Lithium—GSK3B—hematopoietic system—hematologic cancer	0.0105	0.0684	CbGeAlD
Lithium—IMPA1—blood—hematologic cancer	0.00943	0.0615	CbGeAlD
Lithium—GSK3B—gonad—hematologic cancer	0.00797	0.052	CbGeAlD
Lithium—IMPA1—testis—hematologic cancer	0.0078	0.0509	CbGeAlD
Lithium—IMPA2—blood—hematologic cancer	0.00708	0.0462	CbGeAlD
Lithium—GSK3B—blood—hematologic cancer	0.00694	0.0453	CbGeAlD
Lithium—GSK3A—gonad—hematologic cancer	0.00693	0.0452	CbGeAlD
Lithium—IMPA2—bone marrow—hematologic cancer	0.00685	0.0447	CbGeAlD
Lithium—GRIA3—testis—hematologic cancer	0.00663	0.0433	CbGeAlD
Lithium—IMPA2—lung—hematologic cancer	0.0062	0.0405	CbGeAlD
Lithium—GSK3B—lung—hematologic cancer	0.00609	0.0397	CbGeAlD
Lithium—GSK3A—blood—hematologic cancer	0.00604	0.0394	CbGeAlD
Lithium—IMPA2—testis—hematologic cancer	0.00585	0.0382	CbGeAlD
Lithium—GSK3A—bone marrow—hematologic cancer	0.00584	0.0381	CbGeAlD
Lithium—GSK3B—testis—hematologic cancer	0.00574	0.0375	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—hematologic cancer	0.00557	1	CbGdCrCtD
Lithium—GSK3A—lung—hematologic cancer	0.00529	0.0345	CbGeAlD
Lithium—GSK3A—testis—hematologic cancer	0.00499	0.0326	CbGeAlD
Lithium—IMPA2—lymph node—hematologic cancer	0.00424	0.0277	CbGeAlD
Lithium—GSK3B—lymph node—hematologic cancer	0.00416	0.0272	CbGeAlD
Lithium—GSK3A—lymph node—hematologic cancer	0.00362	0.0236	CbGeAlD
Lithium—Vision blurred—Prednisone—hematologic cancer	7.76e-05	0.000194	CcSEcCtD
Lithium—Nausea—Thiotepa—hematologic cancer	7.75e-05	0.000193	CcSEcCtD
Lithium—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	7.75e-05	0.000193	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—hematologic cancer	7.73e-05	0.000193	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—hematologic cancer	7.72e-05	0.000193	CcSEcCtD
Lithium—Oedema—Dexamethasone—hematologic cancer	7.71e-05	0.000193	CcSEcCtD
Lithium—Oedema—Betamethasone—hematologic cancer	7.71e-05	0.000193	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—hematologic cancer	7.71e-05	0.000193	CcSEcCtD
Lithium—Diarrhoea—Mitoxantrone—hematologic cancer	7.71e-05	0.000192	CcSEcCtD
Lithium—Diarrhoea—Irinotecan—hematologic cancer	7.71e-05	0.000192	CcSEcCtD
Lithium—Vomiting—Carmustine—hematologic cancer	7.71e-05	0.000192	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—hematologic cancer	7.66e-05	0.000191	CcSEcCtD
Lithium—Dizziness—Vincristine—hematologic cancer	7.65e-05	0.000191	CcSEcCtD
Lithium—Rash—Carmustine—hematologic cancer	7.64e-05	0.000191	CcSEcCtD
Lithium—Dermatitis—Carmustine—hematologic cancer	7.64e-05	0.000191	CcSEcCtD
Lithium—Vomiting—Alitretinoin—hematologic cancer	7.63e-05	0.000191	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—hematologic cancer	7.62e-05	0.00019	CcSEcCtD
Lithium—Feeling abnormal—Prednisolone—hematologic cancer	7.62e-05	0.00019	CcSEcCtD
Lithium—Headache—Carmustine—hematologic cancer	7.59e-05	0.00019	CcSEcCtD
Lithium—Shock—Betamethasone—hematologic cancer	7.59e-05	0.000189	CcSEcCtD
Lithium—Shock—Dexamethasone—hematologic cancer	7.59e-05	0.000189	CcSEcCtD
Lithium—Rash—Alitretinoin—hematologic cancer	7.57e-05	0.000189	CcSEcCtD
Lithium—Agitation—Prednisone—hematologic cancer	7.56e-05	0.000189	CcSEcCtD
Lithium—Dermatitis—Alitretinoin—hematologic cancer	7.56e-05	0.000189	CcSEcCtD
Lithium—Vomiting—Ifosfamide—hematologic cancer	7.55e-05	0.000188	CcSEcCtD
Lithium—Bradycardia—Epirubicin—hematologic cancer	7.53e-05	0.000188	CcSEcCtD
Lithium—Headache—Alitretinoin—hematologic cancer	7.52e-05	0.000188	CcSEcCtD
Lithium—Angioedema—Prednisone—hematologic cancer	7.52e-05	0.000188	CcSEcCtD
Lithium—Diarrhoea—Gemcitabine—hematologic cancer	7.51e-05	0.000187	CcSEcCtD
Lithium—Nausea—Thalidomide—hematologic cancer	7.5e-05	0.000187	CcSEcCtD
Lithium—Dyspepsia—Triamcinolone—hematologic cancer	7.48e-05	0.000187	CcSEcCtD
Lithium—Rash—Ifosfamide—hematologic cancer	7.48e-05	0.000187	CcSEcCtD
Lithium—Dermatitis—Ifosfamide—hematologic cancer	7.48e-05	0.000187	CcSEcCtD
Lithium—Dizziness—Irinotecan—hematologic cancer	7.45e-05	0.000186	CcSEcCtD
Lithium—Abdominal pain—Etoposide—hematologic cancer	7.41e-05	0.000185	CcSEcCtD
Lithium—Body temperature increased—Etoposide—hematologic cancer	7.41e-05	0.000185	CcSEcCtD
Lithium—Vertigo—Prednisone—hematologic cancer	7.4e-05	0.000185	CcSEcCtD
Lithium—Syncope—Prednisone—hematologic cancer	7.38e-05	0.000184	CcSEcCtD
Lithium—Tinnitus—Methotrexate—hematologic cancer	7.37e-05	0.000184	CcSEcCtD
Lithium—Vomiting—Vincristine—hematologic cancer	7.36e-05	0.000184	CcSEcCtD
Lithium—Anorexia—Dexamethasone—hematologic cancer	7.35e-05	0.000184	CcSEcCtD
Lithium—Anorexia—Betamethasone—hematologic cancer	7.35e-05	0.000184	CcSEcCtD
Lithium—Asthenia—Cisplatin—hematologic cancer	7.34e-05	0.000183	CcSEcCtD
Lithium—Fatigue—Triamcinolone—hematologic cancer	7.33e-05	0.000183	CcSEcCtD
Lithium—Rash—Vincristine—hematologic cancer	7.3e-05	0.000182	CcSEcCtD
Lithium—Dermatitis—Vincristine—hematologic cancer	7.29e-05	0.000182	CcSEcCtD
Lithium—Headache—Vincristine—hematologic cancer	7.25e-05	0.000181	CcSEcCtD
Lithium—Loss of consciousness—Prednisone—hematologic cancer	7.23e-05	0.000181	CcSEcCtD
Lithium—Hypotension—Dexamethasone—hematologic cancer	7.21e-05	0.00018	CcSEcCtD
Lithium—Hypotension—Betamethasone—hematologic cancer	7.21e-05	0.00018	CcSEcCtD
Lithium—Nausea—Carmustine—hematologic cancer	7.2e-05	0.00018	CcSEcCtD
Lithium—Vomiting—Mitoxantrone—hematologic cancer	7.16e-05	0.000179	CcSEcCtD
Lithium—Vomiting—Irinotecan—hematologic cancer	7.16e-05	0.000179	CcSEcCtD
Lithium—Nausea—Alitretinoin—hematologic cancer	7.13e-05	0.000178	CcSEcCtD
Lithium—Convulsion—Prednisone—hematologic cancer	7.13e-05	0.000178	CcSEcCtD
Lithium—Rash—Irinotecan—hematologic cancer	7.1e-05	0.000177	CcSEcCtD
Lithium—Rash—Mitoxantrone—hematologic cancer	7.1e-05	0.000177	CcSEcCtD
Lithium—Dermatitis—Irinotecan—hematologic cancer	7.1e-05	0.000177	CcSEcCtD
Lithium—Dermatitis—Mitoxantrone—hematologic cancer	7.1e-05	0.000177	CcSEcCtD
Lithium—Headache—Mitoxantrone—hematologic cancer	7.06e-05	0.000176	CcSEcCtD
Lithium—Headache—Irinotecan—hematologic cancer	7.06e-05	0.000176	CcSEcCtD
Lithium—Nausea—Ifosfamide—hematologic cancer	7.05e-05	0.000176	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	7.03e-05	0.000175	CcSEcCtD
Lithium—Musculoskeletal discomfort—Betamethasone—hematologic cancer	7.03e-05	0.000175	CcSEcCtD
Lithium—Arthralgia—Prednisone—hematologic cancer	7.01e-05	0.000175	CcSEcCtD
Lithium—Feeling abnormal—Triamcinolone—hematologic cancer	7.01e-05	0.000175	CcSEcCtD
Lithium—Diarrhoea—Cisplatin—hematologic cancer	7e-05	0.000175	CcSEcCtD
Lithium—Alopecia—Methotrexate—hematologic cancer	6.98e-05	0.000174	CcSEcCtD
Lithium—Vomiting—Gemcitabine—hematologic cancer	6.98e-05	0.000174	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—hematologic cancer	6.97e-05	0.000174	CcSEcCtD
Lithium—Discomfort—Prednisone—hematologic cancer	6.92e-05	0.000173	CcSEcCtD
Lithium—Rash—Gemcitabine—hematologic cancer	6.92e-05	0.000173	CcSEcCtD
Lithium—Dermatitis—Gemcitabine—hematologic cancer	6.91e-05	0.000173	CcSEcCtD
Lithium—Tinnitus—Epirubicin—hematologic cancer	6.9e-05	0.000172	CcSEcCtD
Lithium—Headache—Gemcitabine—hematologic cancer	6.88e-05	0.000172	CcSEcCtD
Lithium—Nausea—Vincristine—hematologic cancer	6.87e-05	0.000172	CcSEcCtD
Lithium—Dyspepsia—Betamethasone—hematologic cancer	6.79e-05	0.00017	CcSEcCtD
Lithium—Dyspepsia—Dexamethasone—hematologic cancer	6.79e-05	0.00017	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—hematologic cancer	6.74e-05	0.000168	CcSEcCtD
Lithium—Asthenia—Etoposide—hematologic cancer	6.72e-05	0.000168	CcSEcCtD
Lithium—Body temperature increased—Triamcinolone—hematologic cancer	6.72e-05	0.000168	CcSEcCtD
Lithium—Oedema—Prednisone—hematologic cancer	6.72e-05	0.000168	CcSEcCtD
Lithium—Decreased appetite—Dexamethasone—hematologic cancer	6.71e-05	0.000167	CcSEcCtD
Lithium—Decreased appetite—Betamethasone—hematologic cancer	6.71e-05	0.000167	CcSEcCtD
Lithium—Nausea—Mitoxantrone—hematologic cancer	6.69e-05	0.000167	CcSEcCtD
Lithium—Nausea—Irinotecan—hematologic cancer	6.69e-05	0.000167	CcSEcCtD
Lithium—Fatigue—Betamethasone—hematologic cancer	6.65e-05	0.000166	CcSEcCtD
Lithium—Fatigue—Dexamethasone—hematologic cancer	6.65e-05	0.000166	CcSEcCtD
Lithium—Shock—Prednisone—hematologic cancer	6.61e-05	0.000165	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—hematologic cancer	6.61e-05	0.000165	CcSEcCtD
Lithium—Alopecia—Epirubicin—hematologic cancer	6.53e-05	0.000163	CcSEcCtD
Lithium—Nausea—Gemcitabine—hematologic cancer	6.52e-05	0.000163	CcSEcCtD
Lithium—Vomiting—Cisplatin—hematologic cancer	6.5e-05	0.000162	CcSEcCtD
Lithium—Vision blurred—Methotrexate—hematologic cancer	6.48e-05	0.000162	CcSEcCtD
Lithium—Rash—Cisplatin—hematologic cancer	6.45e-05	0.000161	CcSEcCtD
Lithium—Dermatitis—Cisplatin—hematologic cancer	6.44e-05	0.000161	CcSEcCtD
Lithium—Diarrhoea—Etoposide—hematologic cancer	6.41e-05	0.00016	CcSEcCtD
Lithium—Anorexia—Prednisone—hematologic cancer	6.4e-05	0.00016	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—hematologic cancer	6.38e-05	0.000159	CcSEcCtD
Lithium—Feeling abnormal—Dexamethasone—hematologic cancer	6.36e-05	0.000159	CcSEcCtD
Lithium—Feeling abnormal—Betamethasone—hematologic cancer	6.36e-05	0.000159	CcSEcCtD
Lithium—Flatulence—Epirubicin—hematologic cancer	6.34e-05	0.000158	CcSEcCtD
Lithium—Gastrointestinal pain—Betamethasone—hematologic cancer	6.31e-05	0.000157	CcSEcCtD
Lithium—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.31e-05	0.000157	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—hematologic cancer	6.3e-05	0.000157	CcSEcCtD
Lithium—Dizziness—Etoposide—hematologic cancer	6.2e-05	0.000155	CcSEcCtD
Lithium—Vertigo—Methotrexate—hematologic cancer	6.18e-05	0.000154	CcSEcCtD
Lithium—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.12e-05	0.000153	CcSEcCtD
Lithium—Dizziness—Prednisolone—hematologic cancer	6.11e-05	0.000153	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—hematologic cancer	6.11e-05	0.000153	CcSEcCtD
Lithium—Asthenia—Triamcinolone—hematologic cancer	6.1e-05	0.000152	CcSEcCtD
Lithium—Body temperature increased—Betamethasone—hematologic cancer	6.1e-05	0.000152	CcSEcCtD
Lithium—Body temperature increased—Dexamethasone—hematologic cancer	6.1e-05	0.000152	CcSEcCtD
Lithium—Abdominal pain—Betamethasone—hematologic cancer	6.1e-05	0.000152	CcSEcCtD
Lithium—Abdominal pain—Dexamethasone—hematologic cancer	6.1e-05	0.000152	CcSEcCtD
Lithium—Nausea—Cisplatin—hematologic cancer	6.08e-05	0.000152	CcSEcCtD
Lithium—Vision blurred—Epirubicin—hematologic cancer	6.07e-05	0.000151	CcSEcCtD
Lithium—Alopecia—Doxorubicin—hematologic cancer	6.05e-05	0.000151	CcSEcCtD
Lithium—Convulsion—Methotrexate—hematologic cancer	5.96e-05	0.000149	CcSEcCtD
Lithium—Vomiting—Etoposide—hematologic cancer	5.96e-05	0.000149	CcSEcCtD
Lithium—Agitation—Epirubicin—hematologic cancer	5.92e-05	0.000148	CcSEcCtD
Lithium—Dyspepsia—Prednisone—hematologic cancer	5.91e-05	0.000148	CcSEcCtD
Lithium—Rash—Etoposide—hematologic cancer	5.91e-05	0.000148	CcSEcCtD
Lithium—Dermatitis—Etoposide—hematologic cancer	5.9e-05	0.000147	CcSEcCtD
Lithium—Headache—Etoposide—hematologic cancer	5.87e-05	0.000147	CcSEcCtD
Lithium—Flatulence—Doxorubicin—hematologic cancer	5.87e-05	0.000147	CcSEcCtD
Lithium—Arthralgia—Methotrexate—hematologic cancer	5.86e-05	0.000146	CcSEcCtD
Lithium—Decreased appetite—Prednisone—hematologic cancer	5.84e-05	0.000146	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—hematologic cancer	5.83e-05	0.000146	CcSEcCtD
Lithium—Rash—Prednisolone—hematologic cancer	5.83e-05	0.000146	CcSEcCtD
Lithium—Dermatitis—Prednisolone—hematologic cancer	5.82e-05	0.000145	CcSEcCtD
Lithium—Fatigue—Prednisone—hematologic cancer	5.79e-05	0.000145	CcSEcCtD
Lithium—Headache—Prednisolone—hematologic cancer	5.79e-05	0.000145	CcSEcCtD
Lithium—Discomfort—Methotrexate—hematologic cancer	5.79e-05	0.000144	CcSEcCtD
Lithium—Vertigo—Epirubicin—hematologic cancer	5.78e-05	0.000144	CcSEcCtD
Lithium—Syncope—Epirubicin—hematologic cancer	5.77e-05	0.000144	CcSEcCtD
Lithium—Confusional state—Methotrexate—hematologic cancer	5.66e-05	0.000141	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—hematologic cancer	5.66e-05	0.000141	CcSEcCtD
Lithium—Dizziness—Triamcinolone—hematologic cancer	5.62e-05	0.00014	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—hematologic cancer	5.61e-05	0.00014	CcSEcCtD
Lithium—Convulsion—Epirubicin—hematologic cancer	5.58e-05	0.000139	CcSEcCtD
Lithium—Nausea—Etoposide—hematologic cancer	5.57e-05	0.000139	CcSEcCtD
Lithium—Feeling abnormal—Prednisone—hematologic cancer	5.54e-05	0.000138	CcSEcCtD
Lithium—Asthenia—Dexamethasone—hematologic cancer	5.53e-05	0.000138	CcSEcCtD
Lithium—Asthenia—Betamethasone—hematologic cancer	5.53e-05	0.000138	CcSEcCtD
Lithium—Gastrointestinal pain—Prednisone—hematologic cancer	5.49e-05	0.000137	CcSEcCtD
Lithium—Nausea—Prednisolone—hematologic cancer	5.49e-05	0.000137	CcSEcCtD
Lithium—Arthralgia—Epirubicin—hematologic cancer	5.48e-05	0.000137	CcSEcCtD
Lithium—Agitation—Doxorubicin—hematologic cancer	5.47e-05	0.000137	CcSEcCtD
Lithium—Discomfort—Epirubicin—hematologic cancer	5.42e-05	0.000135	CcSEcCtD
Lithium—Vomiting—Triamcinolone—hematologic cancer	5.41e-05	0.000135	CcSEcCtD
Lithium—Rash—Triamcinolone—hematologic cancer	5.36e-05	0.000134	CcSEcCtD
Lithium—Dry mouth—Epirubicin—hematologic cancer	5.36e-05	0.000134	CcSEcCtD
Lithium—Dermatitis—Triamcinolone—hematologic cancer	5.36e-05	0.000134	CcSEcCtD
Lithium—Vertigo—Doxorubicin—hematologic cancer	5.35e-05	0.000134	CcSEcCtD
Lithium—Anorexia—Methotrexate—hematologic cancer	5.35e-05	0.000134	CcSEcCtD
Lithium—Syncope—Doxorubicin—hematologic cancer	5.34e-05	0.000133	CcSEcCtD
Lithium—Headache—Triamcinolone—hematologic cancer	5.33e-05	0.000133	CcSEcCtD
Lithium—Abdominal pain—Prednisone—hematologic cancer	5.31e-05	0.000133	CcSEcCtD
Lithium—Body temperature increased—Prednisone—hematologic cancer	5.31e-05	0.000133	CcSEcCtD
Lithium—Confusional state—Epirubicin—hematologic cancer	5.3e-05	0.000132	CcSEcCtD
Lithium—Diarrhoea—Dexamethasone—hematologic cancer	5.28e-05	0.000132	CcSEcCtD
Lithium—Diarrhoea—Betamethasone—hematologic cancer	5.28e-05	0.000132	CcSEcCtD
Lithium—Oedema—Epirubicin—hematologic cancer	5.25e-05	0.000131	CcSEcCtD
Lithium—Hypotension—Methotrexate—hematologic cancer	5.25e-05	0.000131	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—hematologic cancer	5.24e-05	0.000131	CcSEcCtD
Lithium—Shock—Epirubicin—hematologic cancer	5.17e-05	0.000129	CcSEcCtD
Lithium—Convulsion—Doxorubicin—hematologic cancer	5.16e-05	0.000129	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.11e-05	0.000128	CcSEcCtD
Lithium—Dizziness—Betamethasone—hematologic cancer	5.1e-05	0.000127	CcSEcCtD
Lithium—Dizziness—Dexamethasone—hematologic cancer	5.1e-05	0.000127	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—hematologic cancer	5.07e-05	0.000127	CcSEcCtD
Lithium—Nausea—Triamcinolone—hematologic cancer	5.05e-05	0.000126	CcSEcCtD
Lithium—Discomfort—Doxorubicin—hematologic cancer	5.01e-05	0.000125	CcSEcCtD
Lithium—Anorexia—Epirubicin—hematologic cancer	5.01e-05	0.000125	CcSEcCtD
Lithium—Somnolence—Methotrexate—hematologic cancer	4.99e-05	0.000125	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—hematologic cancer	4.96e-05	0.000124	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—hematologic cancer	4.94e-05	0.000123	CcSEcCtD
Lithium—Hypotension—Epirubicin—hematologic cancer	4.91e-05	0.000123	CcSEcCtD
Lithium—Vomiting—Dexamethasone—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Lithium—Vomiting—Betamethasone—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Lithium—Confusional state—Doxorubicin—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—hematologic cancer	4.88e-05	0.000122	CcSEcCtD
Lithium—Rash—Betamethasone—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Lithium—Rash—Dexamethasone—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Lithium—Oedema—Doxorubicin—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Lithium—Dermatitis—Dexamethasone—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Lithium—Dermatitis—Betamethasone—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Lithium—Fatigue—Methotrexate—hematologic cancer	4.84e-05	0.000121	CcSEcCtD
Lithium—Headache—Dexamethasone—hematologic cancer	4.83e-05	0.000121	CcSEcCtD
Lithium—Headache—Betamethasone—hematologic cancer	4.83e-05	0.000121	CcSEcCtD
Lithium—Asthenia—Prednisone—hematologic cancer	4.82e-05	0.00012	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.79e-05	0.000119	CcSEcCtD
Lithium—Shock—Doxorubicin—hematologic cancer	4.78e-05	0.000119	CcSEcCtD
Lithium—Somnolence—Epirubicin—hematologic cancer	4.67e-05	0.000117	CcSEcCtD
Lithium—Anorexia—Doxorubicin—hematologic cancer	4.63e-05	0.000116	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—hematologic cancer	4.63e-05	0.000115	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—hematologic cancer	4.62e-05	0.000115	CcSEcCtD
Lithium—Diarrhoea—Prednisone—hematologic cancer	4.6e-05	0.000115	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—hematologic cancer	4.59e-05	0.000115	CcSEcCtD
Lithium—Nausea—Dexamethasone—hematologic cancer	4.58e-05	0.000114	CcSEcCtD
Lithium—Nausea—Betamethasone—hematologic cancer	4.58e-05	0.000114	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—hematologic cancer	4.57e-05	0.000114	CcSEcCtD
Lithium—Hypotension—Doxorubicin—hematologic cancer	4.54e-05	0.000113	CcSEcCtD
Lithium—Fatigue—Epirubicin—hematologic cancer	4.53e-05	0.000113	CcSEcCtD
Lithium—Dizziness—Prednisone—hematologic cancer	4.44e-05	0.000111	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—hematologic cancer	4.44e-05	0.000111	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—hematologic cancer	4.44e-05	0.000111	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.43e-05	0.000111	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—hematologic cancer	4.33e-05	0.000108	CcSEcCtD
Lithium—Somnolence—Doxorubicin—hematologic cancer	4.32e-05	0.000108	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—hematologic cancer	4.3e-05	0.000107	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—hematologic cancer	4.28e-05	0.000107	CcSEcCtD
Lithium—Vomiting—Prednisone—hematologic cancer	4.27e-05	0.000107	CcSEcCtD
Lithium—Rash—Prednisone—hematologic cancer	4.24e-05	0.000106	CcSEcCtD
Lithium—Dermatitis—Prednisone—hematologic cancer	4.23e-05	0.000106	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—hematologic cancer	4.23e-05	0.000105	CcSEcCtD
Lithium—Headache—Prednisone—hematologic cancer	4.21e-05	0.000105	CcSEcCtD
Lithium—Fatigue—Doxorubicin—hematologic cancer	4.19e-05	0.000105	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—hematologic cancer	4.15e-05	0.000104	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—hematologic cancer	4.15e-05	0.000104	CcSEcCtD
Lithium—Asthenia—Methotrexate—hematologic cancer	4.03e-05	0.000101	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—hematologic cancer	4.01e-05	0.0001	CcSEcCtD
Lithium—Nausea—Prednisone—hematologic cancer	3.99e-05	9.96e-05	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.98e-05	9.92e-05	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—hematologic cancer	3.84e-05	9.59e-05	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—hematologic cancer	3.84e-05	9.59e-05	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—hematologic cancer	3.84e-05	9.59e-05	CcSEcCtD
Lithium—Asthenia—Epirubicin—hematologic cancer	3.77e-05	9.41e-05	CcSEcCtD
Lithium—Dizziness—Methotrexate—hematologic cancer	3.71e-05	9.27e-05	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—hematologic cancer	3.59e-05	8.97e-05	CcSEcCtD
Lithium—Vomiting—Methotrexate—hematologic cancer	3.57e-05	8.91e-05	CcSEcCtD
Lithium—Rash—Methotrexate—hematologic cancer	3.54e-05	8.84e-05	CcSEcCtD
Lithium—Dermatitis—Methotrexate—hematologic cancer	3.54e-05	8.83e-05	CcSEcCtD
Lithium—Headache—Methotrexate—hematologic cancer	3.52e-05	8.78e-05	CcSEcCtD
Lithium—Asthenia—Doxorubicin—hematologic cancer	3.49e-05	8.71e-05	CcSEcCtD
Lithium—Dizziness—Epirubicin—hematologic cancer	3.47e-05	8.67e-05	CcSEcCtD
Lithium—Vomiting—Epirubicin—hematologic cancer	3.34e-05	8.34e-05	CcSEcCtD
Lithium—Nausea—Methotrexate—hematologic cancer	3.33e-05	8.32e-05	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—hematologic cancer	3.33e-05	8.3e-05	CcSEcCtD
Lithium—Rash—Epirubicin—hematologic cancer	3.31e-05	8.27e-05	CcSEcCtD
Lithium—Dermatitis—Epirubicin—hematologic cancer	3.31e-05	8.26e-05	CcSEcCtD
Lithium—Headache—Epirubicin—hematologic cancer	3.29e-05	8.22e-05	CcSEcCtD
Lithium—Dizziness—Doxorubicin—hematologic cancer	3.21e-05	8.03e-05	CcSEcCtD
Lithium—Nausea—Epirubicin—hematologic cancer	3.12e-05	7.79e-05	CcSEcCtD
Lithium—Vomiting—Doxorubicin—hematologic cancer	3.09e-05	7.72e-05	CcSEcCtD
Lithium—Rash—Doxorubicin—hematologic cancer	3.07e-05	7.65e-05	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—hematologic cancer	3.06e-05	7.64e-05	CcSEcCtD
Lithium—Headache—Doxorubicin—hematologic cancer	3.05e-05	7.6e-05	CcSEcCtD
Lithium—Nausea—Doxorubicin—hematologic cancer	2.89e-05	7.21e-05	CcSEcCtD
Lithium—GSK3A—Disease—PIK3R1—hematologic cancer	1.38e-05	3.13e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—hematologic cancer	1.38e-05	3.13e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—hematologic cancer	1.38e-05	3.13e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—hematologic cancer	1.38e-05	3.12e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BAD—hematologic cancer	1.37e-05	3.12e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKBIA—hematologic cancer	1.37e-05	3.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT1—hematologic cancer	1.37e-05	3.11e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—hematologic cancer	1.35e-05	3.06e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFB—hematologic cancer	1.35e-05	3.06e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—hematologic cancer	1.35e-05	3.06e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—JAK2—hematologic cancer	1.34e-05	3.04e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR3—hematologic cancer	1.34e-05	3.04e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—hematologic cancer	1.34e-05	3.03e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD80—hematologic cancer	1.33e-05	3.02e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—hematologic cancer	1.33e-05	3.02e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—hematologic cancer	1.33e-05	3.01e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSC2—hematologic cancer	1.32e-05	2.99e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—hematologic cancer	1.31e-05	2.98e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—hematologic cancer	1.31e-05	2.97e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTPN11—hematologic cancer	1.31e-05	2.97e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—hematologic cancer	1.3e-05	2.94e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—hematologic cancer	1.29e-05	2.94e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK3—hematologic cancer	1.29e-05	2.93e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—hematologic cancer	1.28e-05	2.91e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRB2—hematologic cancer	1.28e-05	2.91e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFA—hematologic cancer	1.28e-05	2.9e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—hematologic cancer	1.28e-05	2.9e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—hematologic cancer	1.27e-05	2.89e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—hematologic cancer	1.27e-05	2.89e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—hematologic cancer	1.27e-05	2.89e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—hematologic cancer	1.27e-05	2.89e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—FOS—hematologic cancer	1.27e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BAD—hematologic cancer	1.27e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR3—hematologic cancer	1.27e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—hematologic cancer	1.27e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREB1—hematologic cancer	1.27e-05	2.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KITLG—hematologic cancer	1.26e-05	2.86e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NOTCH1—hematologic cancer	1.26e-05	2.85e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK14—hematologic cancer	1.26e-05	2.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—hematologic cancer	1.24e-05	2.81e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6R—hematologic cancer	1.24e-05	2.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREBBP—hematologic cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—hematologic cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT5A—hematologic cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—hematologic cancer	1.23e-05	2.79e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CD80—hematologic cancer	1.23e-05	2.79e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KIT—hematologic cancer	1.23e-05	2.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN2B—hematologic cancer	1.22e-05	2.77e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FN1—hematologic cancer	1.22e-05	2.76e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTPN11—hematologic cancer	1.21e-05	2.74e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BAD—hematologic cancer	1.2e-05	2.73e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKBIA—hematologic cancer	1.2e-05	2.73e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—hematologic cancer	1.2e-05	2.71e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—hematologic cancer	1.19e-05	2.71e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—hematologic cancer	1.19e-05	2.71e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH1—hematologic cancer	1.19e-05	2.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CD86—hematologic cancer	1.18e-05	2.68e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—hematologic cancer	1.18e-05	2.68e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAP2K1—hematologic cancer	1.18e-05	2.67e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—hematologic cancer	1.17e-05	2.65e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CREB1—hematologic cancer	1.17e-05	2.65e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK8—hematologic cancer	1.17e-05	2.65e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CD80—hematologic cancer	1.17e-05	2.65e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—hematologic cancer	1.16e-05	2.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIT—hematologic cancer	1.16e-05	2.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—hematologic cancer	1.16e-05	2.64e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—hematologic cancer	1.16e-05	2.64e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NCOR1—hematologic cancer	1.16e-05	2.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—hematologic cancer	1.15e-05	2.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGF1—hematologic cancer	1.15e-05	2.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CSF2—hematologic cancer	1.15e-05	2.6e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTPN11—hematologic cancer	1.14e-05	2.6e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6R—hematologic cancer	1.14e-05	2.59e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CREBBP—hematologic cancer	1.14e-05	2.58e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—hematologic cancer	1.14e-05	2.58e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—hematologic cancer	1.13e-05	2.57e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FOXO1—hematologic cancer	1.13e-05	2.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRB—hematologic cancer	1.13e-05	2.56e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGF2—hematologic cancer	1.12e-05	2.54e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—hematologic cancer	1.12e-05	2.54e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—hematologic cancer	1.12e-05	2.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRA—hematologic cancer	1.11e-05	2.52e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREB1—hematologic cancer	1.11e-05	2.51e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKCG—hematologic cancer	1.11e-05	2.51e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAK1—hematologic cancer	1.11e-05	2.51e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—hematologic cancer	1.11e-05	2.51e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3R1—hematologic cancer	1.1e-05	2.51e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—hematologic cancer	1.1e-05	2.5e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—hematologic cancer	1.1e-05	2.5e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—hematologic cancer	1.09e-05	2.48e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAP2K1—hematologic cancer	1.09e-05	2.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL2—hematologic cancer	1.08e-05	2.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6R—hematologic cancer	1.08e-05	2.45e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—hematologic cancer	1.08e-05	2.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREBBP—hematologic cancer	1.08e-05	2.45e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JAK2—hematologic cancer	1.07e-05	2.44e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—hematologic cancer	1.07e-05	2.43e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—hematologic cancer	1.07e-05	2.42e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—hematologic cancer	1.07e-05	2.42e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—hematologic cancer	1.06e-05	2.41e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2—hematologic cancer	1.06e-05	2.41e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—hematologic cancer	1.05e-05	2.39e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—hematologic cancer	1.05e-05	2.38e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MDM2—hematologic cancer	1.05e-05	2.38e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—FGF2—hematologic cancer	1.03e-05	2.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2RA—hematologic cancer	1.03e-05	2.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAP2K1—hematologic cancer	1.03e-05	2.34e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—hematologic cancer	1.02e-05	2.33e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—hematologic cancer	1.02e-05	2.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—hematologic cancer	1.02e-05	2.32e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—hematologic cancer	1.02e-05	2.32e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3R1—hematologic cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—hematologic cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—hematologic cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK3—hematologic cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—hematologic cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFB—hematologic cancer	9.96e-06	2.26e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—JAK2—hematologic cancer	9.91e-06	2.25e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—hematologic cancer	9.87e-06	2.24e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—hematologic cancer	9.87e-06	2.24e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—hematologic cancer	9.84e-06	2.23e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—hematologic cancer	9.82e-06	2.23e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGF2—hematologic cancer	9.8e-06	2.22e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSC2—hematologic cancer	9.74e-06	2.21e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—hematologic cancer	9.67e-06	2.2e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3R1—hematologic cancer	9.66e-06	2.19e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—hematologic cancer	9.57e-06	2.17e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—hematologic cancer	9.48e-06	2.15e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—hematologic cancer	9.45e-06	2.14e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—hematologic cancer	9.41e-06	2.14e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—hematologic cancer	9.41e-06	2.14e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK3—hematologic cancer	9.4e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—hematologic cancer	9.4e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—hematologic cancer	9.39e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JAK2—hematologic cancer	9.39e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR3—hematologic cancer	9.37e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—hematologic cancer	9.36e-06	2.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK14—hematologic cancer	9.27e-06	2.11e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—hematologic cancer	9.17e-06	2.08e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—hematologic cancer	9.15e-06	2.08e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—hematologic cancer	9.15e-06	2.08e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—hematologic cancer	9.12e-06	2.07e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—hematologic cancer	9.11e-06	2.07e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—hematologic cancer	9.1e-06	2.07e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FN1—hematologic cancer	8.99e-06	2.04e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—hematologic cancer	8.92e-06	2.02e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—hematologic cancer	8.92e-06	2.02e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BAD—hematologic cancer	8.88e-06	2.02e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKBIA—hematologic cancer	8.88e-06	2.02e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—hematologic cancer	8.83e-06	2e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—hematologic cancer	8.83e-06	2e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—hematologic cancer	8.81e-06	2e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH1—hematologic cancer	8.79e-06	2e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—hematologic cancer	8.71e-06	1.98e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK8—hematologic cancer	8.62e-06	1.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CD80—hematologic cancer	8.62e-06	1.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—hematologic cancer	8.6e-06	1.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—hematologic cancer	8.6e-06	1.95e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—hematologic cancer	8.45e-06	1.92e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTPN11—hematologic cancer	8.45e-06	1.92e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—hematologic cancer	8.41e-06	1.91e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—hematologic cancer	8.4e-06	1.91e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—hematologic cancer	8.37e-06	1.9e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—hematologic cancer	8.37e-06	1.9e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—hematologic cancer	8.2e-06	1.86e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—hematologic cancer	8.19e-06	1.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREB1—hematologic cancer	8.19e-06	1.86e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—hematologic cancer	8.17e-06	1.85e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—hematologic cancer	8.15e-06	1.85e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—hematologic cancer	8.13e-06	1.85e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—hematologic cancer	8.08e-06	1.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL2—hematologic cancer	8.01e-06	1.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6R—hematologic cancer	7.99e-06	1.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—hematologic cancer	7.98e-06	1.81e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREBBP—hematologic cancer	7.97e-06	1.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—hematologic cancer	7.97e-06	1.81e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—hematologic cancer	7.88e-06	1.79e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—hematologic cancer	7.86e-06	1.78e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—hematologic cancer	7.78e-06	1.77e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—hematologic cancer	7.76e-06	1.76e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—hematologic cancer	7.76e-06	1.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—hematologic cancer	7.72e-06	1.75e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—hematologic cancer	7.71e-06	1.75e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAP2K1—hematologic cancer	7.61e-06	1.73e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—hematologic cancer	7.56e-06	1.72e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—hematologic cancer	7.54e-06	1.71e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK8—hematologic cancer	7.54e-06	1.71e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK3—hematologic cancer	7.53e-06	1.71e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—hematologic cancer	7.45e-06	1.69e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—hematologic cancer	7.35e-06	1.67e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—hematologic cancer	7.27e-06	1.65e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—hematologic cancer	7.25e-06	1.65e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGF2—hematologic cancer	7.24e-06	1.64e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—hematologic cancer	7.18e-06	1.63e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—hematologic cancer	7.15e-06	1.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3R1—hematologic cancer	7.14e-06	1.62e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—hematologic cancer	6.96e-06	1.58e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK3—hematologic cancer	6.95e-06	1.58e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAK2—hematologic cancer	6.94e-06	1.57e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—hematologic cancer	6.89e-06	1.56e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—hematologic cancer	6.88e-06	1.56e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—hematologic cancer	6.87e-06	1.56e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—hematologic cancer	6.87e-06	1.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—hematologic cancer	6.77e-06	1.54e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—hematologic cancer	6.76e-06	1.54e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—hematologic cancer	6.76e-06	1.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—hematologic cancer	6.74e-06	1.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—hematologic cancer	6.59e-06	1.5e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—hematologic cancer	6.59e-06	1.5e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK3—hematologic cancer	6.58e-06	1.49e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—hematologic cancer	6.4e-06	1.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—hematologic cancer	6.39e-06	1.45e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—hematologic cancer	6.34e-06	1.44e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—hematologic cancer	6.24e-06	1.42e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—hematologic cancer	6.21e-06	1.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—hematologic cancer	6.18e-06	1.4e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—hematologic cancer	6.06e-06	1.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—hematologic cancer	6.05e-06	1.37e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—hematologic cancer	5.92e-06	1.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—hematologic cancer	5.9e-06	1.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—hematologic cancer	5.89e-06	1.34e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—hematologic cancer	5.75e-06	1.3e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—hematologic cancer	5.74e-06	1.3e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—hematologic cancer	5.71e-06	1.3e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—hematologic cancer	5.69e-06	1.29e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK8—hematologic cancer	5.57e-06	1.26e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—hematologic cancer	5.5e-06	1.25e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—hematologic cancer	5.44e-06	1.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—hematologic cancer	5.43e-06	1.23e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—hematologic cancer	5.31e-06	1.2e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—hematologic cancer	5.28e-06	1.2e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—hematologic cancer	5.26e-06	1.19e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—hematologic cancer	5.14e-06	1.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—hematologic cancer	5.09e-06	1.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—hematologic cancer	5.08e-06	1.15e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—hematologic cancer	5.08e-06	1.15e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—hematologic cancer	5.08e-06	1.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—hematologic cancer	5.03e-06	1.14e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK3—hematologic cancer	4.87e-06	1.1e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—hematologic cancer	4.81e-06	1.09e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—hematologic cancer	4.73e-06	1.07e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—hematologic cancer	4.72e-06	1.07e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—hematologic cancer	4.69e-06	1.06e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—hematologic cancer	4.44e-06	1.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—hematologic cancer	4.37e-06	9.92e-06	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—hematologic cancer	4.02e-06	9.12e-06	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—hematologic cancer	3.89e-06	8.82e-06	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—hematologic cancer	3.72e-06	8.44e-06	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—hematologic cancer	3.56e-06	8.07e-06	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—hematologic cancer	3.28e-06	7.45e-06	CbGpPWpGaD
